This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?

·4 min read
This Growth Stock Has Soared Over 200% Year to Date -- Is It a Buy?

More than two years into the pandemic, hospitalized patients with severe cases may get a game-changing treatment.